Aura Day 2025 D E C E M B E R 2 0 2 5 To find, mine and provide the most important and essential ores that allow the world and mankind to create, innovate and prosper. Aura Day team Seasoned Management Team Glauber Luvizotto Isabela Dumont Head People, Communications & Sustainability Natasha Utescher Head of IR and Treasury Frederico Silva Director of Operations Aura Borborema, Brazil Francisco do Carmo Director of Operations Aura Minosa, Honduras Pitágoras Costa Director of Projects and Construction Richar ...

Strategic Transactions Overview - Antero Resources (AR) is acquiring HG Energy's upstream business for $2.8 billion plus hedge book, and Antero Midstream (AM) is acquiring HG Energy's midstream business for $1.1 billion[10] - AR is divesting non-core Utica assets, with the upstream assets being sold for $800 million and the midstream assets for $400 million[10] - The HG Energy acquisition is expected to add over 400 drilling locations in the Marcellus Shale core, with 75% being liquids-rich[11, 44] Financial Impact and Synergies - The acquisition is projected to be 30%+ accretive to operating cash flow, free cash flow, and NAV per share metrics[12, 28] - Identified synergies from the HG Energy acquisition are estimated at $950 million (PV-10)[11, 25] - AR anticipates reducing its cost structure by approximately $0.25/Mcfe due to the HG Energy acquisition[12, 53] Production and Capital Expenditure - Pro forma production outlook for 2027 is projected to be between 4,400 and 4,500 MMcfe/d[15] - Targeted maintenance capital expenditure for 2026 is projected to be between $1.1 billion and $1.2 billion[17] Financing and Balance Sheet - The HG Energy acquisition is expected to be fully financed by 2028 through a combination of AR's free cash flow, proceeds from the Utica divestiture, and hedged free cash flow of the acquired assets[13] - AR expects to maintain leverage below 1.0x in 2026 and expects reaffirmed investment grade credit ratings[30, 33] Antero Midstream (AM) Transactions - AM is acquiring HG Midstream for $1.1 billion and divesting Utica Midstream for $400 million[10, 40] - The HG Midstream acquisition is expected to generate approximately $110 million in free cash flow[40]

Disclaimer About Forward-Looking Statements & Third-Party Sources INVESTOR PRESENTATION This presentation (this "Investor Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential transaction (the "Transaction") between ContextLogic Holdings Inc., and its subsidiaries (the "Company"), US Salt Parent Holdings, LLC and its subsidiaries ("US Salt"), affiliates of Abrams Capital Management, L.P. ("Abra ...

Strategic Transactions - Antero Resources (AR) is acquiring HG Energy in the core Marcellus Shale and divesting non-core Utica assets[6, 7] - AR is acquiring HG Energy's upstream business for $2.8 billion plus hedge book, and Antero Midstream (AM) is acquiring HG Energy's midstream business for $1.1 billion[10] - AR is divesting upstream assets in Utica for $800 million, and AM is divesting midstream assets in Utica for $400 million[10] HG Acquisition - The HG Acquisition is expected to add approximately 400 additional locations in the Marcellus Shale core, with 75% being liquids-rich[11, 44] - The acquisition is projected to provide ~$950 million in identified synergies[11] - The acquisition is expected to reduce the cost structure by ~$0.25/Mcfe and increase margins by $0.15 to $0.20 per Mcfe[12] - The acquisition is expected to be 30%+ accretive to operating cash flow, free cash flow, and NAV per share metrics[12, 28] - The acquisition is fully financed and expected to be paid off by 2028 through a combination of AR Free Cash Flow, proceeds from the Utica divestiture, and hedged Free Cash Flow of the acquired assets[13] Pro Forma Outlook - Pro forma production outlook for 2027 is projected to be between 4,400 and 4,500 MMcfe/d[15] Utica Divestiture - The Utica divestiture is expected to generate $800 million in proceeds[10] - The Utica divestiture is expected to have a 2026E Free Cash Flow of ~$55 million[9] Antero Midstream (AM) - AM is acquiring HG Midstream for $1.1 billion and divesting Utica Midstream for $400 million[10, 40] - HG Midstream acquisition is expected to add >400 dedicated locations (75% liquids)[42, 44] - HG Midstream has ~900 MMcf/d of throughput[41]

Business Transformation & Strategy - Ingevity is simplifying its business by exiting Industrial Specialties, Advanced Polymer Technologies (APT), and Road Markings [11, 12] - The company is establishing "New Ingevity" with two core businesses: Performance Materials and Pavement Technologies [12] - New Ingevity will leverage strong cash flow and divestiture proceeds to invest in organic growth, reduce debt, and return capital to shareholders [11] Financial Performance & Outlook - Pro Forma 2025E Revenue for New Ingevity is approximately $900 million [14] - Pro Forma 2025E EBITDA is approximately $335 million, with an EBITDA margin of approximately 37% [14] - The company expects to generate over $200 million of free cash flow per year in 2026 and 2027 [71] - New Ingevity projects 2027E Revenue of $940-980 million and EBITDA of $350-370 million, resulting in an EBITDA Margin of 36-39% [61] - The company aims to maintain a leverage target of 2 to 2.5x [71] Segment Specifics - Performance Materials expects 2025E revenue of approximately $600 million with EBITDA margins exceeding 50% [27] - Pavement Technologies expects 2025E revenue of approximately $300 million with EBITDA margins of 33% [49] Capital Allocation - The company plans to use divestiture proceeds to repurchase approximately $300 million of shares over the next 2 years [75]

Divestiture of the Packaging Sector December 8, 2025 In this presentation, unless otherwise indicated, all financial data are prepared in accordance with International Financial Reporting Standards (IFRS) and the term ''dollars'' as well as the symbol ''$'' designate Canadian dollars. In this document, we also use non-IFRS financial measures for which a complete definition is presented below and for which a reconciliation to financial information in accordance with IFRS is presented in slide 16 "Reconciliat ...

Positive Interim Clinical Data from INLIGHT Trial of WVE-007 in Obesity Investor Presentation December 8, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ther ...

Aleniglipron Efficacy - In the Phase 2b ACCESS trial, Aleniglipron achieved placebo-adjusted mean weight loss of 82% at 45 mg, 98% at 90 mg, and 113% at 120 mg at 36 weeks[41] - Exploratory ACCESS II study showed placebo-adjusted mean weight loss at 36 weeks of 141% at 120 mg, 144% at 180 mg, and 153% at 240 mg[72] - ACCESS Open Label Extension (OLE) study indicated that weight loss continues to increase in all arms through Week 44, with no evidence of a weight loss plateau[50] Aleniglipron Tolerability and Safety - Phase 2b ACCESS trial showed an overall 104% AE-related treatment discontinuation rate, with GI-related AEs consistent with the GLP-1RA class[41] - In the Exploratory ACCESS II trial, participants who achieved re-randomization experienced no AE-related treatment discontinuations up to the 240 mg dose at week 36[72] - Body Composition study showed improved tolerability with a lower 25 mg starting dose, with no treatment discontinuations due to AEs after a median treatment of approximately 10 weeks[83] - Across all studies with over 500 participants treated up to 44 weeks, there were no events of drug-induced liver injury, off-target safety signals, or QTc prolongation[96] Market Opportunity and Scalability - The overweight and obesity market includes over 800 million people worldwide, with projections of 15 billion people by 2030[14] - The total addressable market for obesity treatments is estimated to be over $100 billion[14] - Oral small molecules like Aleniglipron can scale to meet the needs of the global obesity patient population, offering potential advantages in accessibility and cost compared to injectable peptides[12, 15]

KT-621, Oral STAT6 Degrader, Phase 1b Results 1 Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief Executive Officer KT-621 BroADen Phase 1b Data Jared Gollob, MD Chief Medical Officer Closing Remarks Nello Mainolfi, PhD Founder, President and Chief Executive Officer Question and Answer Session 2 Forward Looking Statements This presentation contains forward-looking statements within the me ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy December 8, 2025 Forward Looking Statements This presentation discusses an investigational product whose safety and efficacy have not been established. This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regardi ...